<DOC>
	<DOCNO>NCT01432574</DOCNO>
	<brief_summary>The purpose study test effectiveness research study vaccine , Gardasil , men age 27-45 complete 4 year observation The Human Papillomavirus [ HPV ] infection men ( HIM ) Study .</brief_summary>
	<brief_title>Study Gardasil Mid-Adult Males ( MAM )</brief_title>
	<detailed_description>The MAM Study prospective pilot intervention trial investigate pattern human papillomavirus ( HPV ) vaccine immunogenicity men , age 27-45 year , men receive Gardasil . Gardasil administer 0 , 2 , 6 month . Blood draw 0 7 month provide quadrivalent HPV antibody serologic profile . Participants also complete survey via computer-assisted interview ( CASI ) Day 1 Month 7 record sexual behavior . Our overall goal test efficacy Gardasil reduce HPV 6 , 11 , 16 , 18 persistent infection among men external genital epithelium , anal canal , oral cavity , reduce lesion cause HPV type external genital epithelium anal canal . The purpose Phase II trial establish immunogenicity Gardasil among mid-adult men establish infrastructure build large Phase III trial future .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Men complete 4 year followup ongoing international prospective natural history study HPV men ( The HIM Study ) Willing comply 4 schedule visit within 7month period Have receive HPV vaccine Have prior diagnosis penile anal cancer Have prior diagnosis high grade anal intraepithelial neoplasia Have diagnose human immunodeficiency virus ( HIV ) /acquired immune deficiency syndrome ( AIDS ) Have history anaphylaxis vaccine Have know impairment immune system Have receive blood product within 6 month enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>27 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HPV</keyword>
</DOC>